The Importance of First-Line Maintenance Therapy in Small Cell Lung Cancer

Small cell lung cancer (SCLC) is one of the most aggressive and difficult-to-treat forms of lung cancer.ⁱ It is typically fast-growing and often diagnosed at an advanced stage. Among patients with SCLC, approximately 70% are diagnosed with extensive-stage disease (ES-SCLC), meaning the cancer has spread beyond one lung and nearby lymph nodes.ⁱⁱ

While many patients initially respond well to treatment, the majority relapse—often within months—and more than 90% of those with metastatic disease experience recurrence within two years.^iii,iv These realities highlight the urgent need to sustain and extend the initial benefits of first-line therapy, an area where maintenance strategies may play a critical role.

The Role of Maintenance Therapy

Maintenance therapy may offer a promising opportunity to shift this trajectory. By helping patients maintain disease control after initial treatment, maintenance approaches may delay progression and improve survival. While many eligible patients do receive ongoing therapy following their first-line regimen, the aggressive biology of ES-SCLC means that relapse often occurs despite continued treatment, underscoring the need for more effective and durable maintenance strategies.^v

“The field of research in small cell lung cancer continues to evolve, and we’re seeing new potential to change how the disease is managed,” said Amal Melhem-Bertrandt, VP, Oncology Therapy Area Head, Clinical Development R&D. “Recent innovations have already advanced the standard of care in the first-line setting. Now new maintenance strategies may help prolong the impact of initial treatment.”

Looking Ahead in SCLC Care

There is still much to do, and given the aggressive nature of SCLC, time is of the essence. As research progresses, maintenance therapy represents a critical opportunity to extend the benefits of first-line treatment before the disease progresses.

At Jazz, we are proud to contribute to the growing body of research aimed at redefining expectations for SCLC care. Together with our partners, we remain committed to advancing science that supports patients at every stage of their journey.

Read more about how Jazz is redefining what’s possible in SCLC care.

References

ⁱParth Desai et al. Small Cell Lung Cancer: New Hope, New Challenges. 1, e2400019(2024). DOI:10.1200/OA.0000000000000001 
ⁱⁱOncoDaily, Small Cell Lung Cancer: Symptoms, Causes, Types, Diagnosis and Treatment, https://oncodaily.com/oncolibrary/cancer-types/small-cell-lung-cancer 
ⁱⁱⁱSaida Y, Watanabe S, Kikuchi T. Extensive-Stage Small-Cell Lung Cancer: Current Landscape and Future Prospects. Onco Targets Ther. 2023 Aug 2;16:657-671. doi: 10.2147/OTT.S272552. PMID: 37551311; PMCID: PMC10404428. 
^ivAPPOS. Extensive-Stage Small-Cell Lung Cancer: Hope Is on the Horizon. https://apponcologysummit.org/extensive-stage-small-cell-lung-cancer-hope-is-on-the-horizon/#:~:text=Staging%20for%20SCLC%20is%20typically,will%20develop%20brain%20metastases%20later. Accessed May 14, 2025. 
^vLuis Paz-Ares, Brinda Gupta, Javier Baena, Stephen V. Liu, Unmet Needs in Maintenance Therapy for Extensive Stage Small Cell Lung Cancer, Clinical Lung Cancer, Volume 26, Issue 3, 2025, Pages 168-178, ISSN 1525-7304, https://doi.org/10.1016/j.cllc.2025.02.015.